Low nirmatrelvir/ritonavir use among patients with rheumatoid arthritis: a signal of concern

Individuals with rheumatoid arthritis (RA) may be at increased risk of severe coronavirus disease 2019 (COVID-19) outcomes. Nirmatrelvir/ritonavir has been shown to reduce the risk for hospitalization and death among patients with COVID-19 at risk for progression to severe disease.

Information

Citation

Kwok TSH, Kuriya B, Eder L, Aghanya V, Gatley JM, Widdifield J. J Rheumatol. 2023; Oct 1 [Epub ahead of print].

Contributing ICES Scientists

Jessica Widdifield

Research Programs

Chronic Disease & Pharmacotherapy

Associated Topics

Associated Sites

ICES Central

Discover More

Journal Article

Time trends in maternal attention-deficit/hyperactivity disorder and medication use in pregnancy

Egsgaard S, Brown HK, Zipursky J, Munk-Olsen T, Babujee A, Patrikar A, Lu M, Vigod SN. J Clin Psychiatry. 2026; 87(3): 26m16321.

Journal Article

Lithium toxicity from angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker co-prescription: a population-based cohort study

Ahmadi F, Muanda FT, McArthur E, Weir M, Garg AX. J Psychopharmacol. 2026; Aug 5 [Epub ahead of print].

Journal Article

Examining the effect of newborn feeding method on postnatal length of stay and healthcare utilisation among Neonates With In-utero SSRI Exposure (NeoWISE): a retrospective cohort study

Cantin C, Li W, Snelgrove-Clarke E, Corsi D, Dennis CL, Ross-White A, Brogly S, Gaudet L. BMJ Paediatr Open. 2026; 10(1): e004689.